Guberina, Maja http://orcid.org/0000-0003-3218-0539
Darwiche, Kaid
Hautzel, Hubertus
Pöttgen, Christoph
Guberina, Nika
Gauler, Thomas
Ploenes, Till
Umutlu, Lale
Theegarten, Dirk
Aigner, Clemens
Eberhardt, Wilfried E. E.
Metzenmacher, Martin
Wiesweg, Marcel
Karpf-Wissel, Rüdiger
Schuler, Martin
Herrmann, Ken
Stuschke, Martin
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 10 June 2021
Accepted: 30 August 2021
First Online: 15 September 2021
Declarations
:
: Ethics committee of the medical faculty, University Duisburg-Essen, UK Essen 19-9056-BO.
: Not applicable.
: Maja Guberina, Nika Guberina, Lale Umutlu, Till Ploenes, Hubertus Hautzel, Dirk Theegarten, Clemens Aigner; Rüdiger Karpf-Wissel. There are no relationships/conditions/circumstances that present a potential conflict of interest. All authors declare that they have no conflict of interest. Christoph Pöttgen reports personal honoraria from Roche Pharma, personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, outside the submitted work. There are no relationships/conditions/circumstances that present a potential conflict of interest. Thomas Gauler: advisory board or consultant: Ipsen, No-vartis, BMS, Eisai; honoraria: BMS, Ipsen, Novartis, MSD, Eisai, Pfizer; traveling expenses: BMS, Ipsen, Novartis, MSD, Eisai, Pfiz-er; stocks: Bayer. Martin Metzenmacher reports honoraria from BMS, Boehringer Ingelheim, MSD, Roche, Takeda. Marcel Wiesweg: Honoraria: Amgen, Boehringer Ingelheim, Novartis, Roche, Takeda. Research Funding: Bristol-Myers Squibb, Takeda. Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Bain Capital, personal fees from MPM Capital, outside the submitted work. Kaid Darwiche received travel grants from Olympus and Boston Scientific. There are no relationships/conditions/circumstances that present a potential conflict of interest. W. E. E. Eberhardt: Honoraria (Advisory board function) Astra Zeneca, BMS, Roche, MSD, Pfizer, Boehringer, Takeda, Eli Lilly, Bayer, Celgene. Honoraria (educational lectures) BMS, MSD Astra Zeneca, Roche, Novartis, Pfizer, Boehringer, Takeda, Abbvie, Celgene, Eli Lilly. Research grant: Eli Lilly, BMS, Astra Zeneca; Other: none. The author declares that no competing interests exist. Martin Schuler: Consultant (compensated): AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Novartis, Roche, Takeda. Stock ownership: none. Honoraries for CME presentations: Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, MSD, Novartis. Research funding to institution: AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, Novartis. MS confirms that the above mentioned funding source was not involved in the study design or materials used, neither in the collection, analysis, and interpretation of data nor in the writing of the paper. Martin Stuschke: Honoraria (Advisory board function) AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Janssen-Cilag Research funding to institution by AstraZeneca in 2019 and 2020. Prof. Dr. Martin Stuschke confirms that the above mentioned funding source was not involved in the study design or materials used, neither in the collection, analysis, and interpretation of data nor in the writing of the paper.